Franklin Genomic Advancements

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HELX and other ETFs, options, and stocks.

About HELX

HELX is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. The listed name for HELX is Franklin Genomic Advancements ETF. 

Index-Tracked
Index-Tracked
Category
Health
CategoryHealth
Number of holdings
70
Number of holdings70
Inception Date
Feb 25, 2020
Inception DateFeb 25, 2020

What's in this fund

Sectors

As of November 12, 2025
Healthcare96.87%
Basic Materials2.32%
Technology0.81%

HELX Key Statistics

AUM
20.85M
AUM20.85M
Price-Earnings ratio
-204.41
Price-Earnings ratio-204.41
30-Day yield
30-Day yield
Average volume
200.60
Average volume200.60
High today
$34.64
High today$34.64
Low today
$34.64
Low today$34.64
Open price
$34.64
Open price$34.64
Volume
699.00
Volume699.00
52 Week high
$35.47
52 Week high$35.47
52 Week low
$23.74
52 Week low$23.74
Expense ratio
0.50
Expense ratio0.50

Stock Snapshot

As of today, Franklin Genomic Advancements(HELX) shares are valued at $34.89. The company's market cap stands at 20.93M, with a P/E ratio of -204.41 and a dividend yield of 14.6%.

On 2025-11-14, Franklin Genomic Advancements(HELX) stock moved within a range of $34.64 to $34.64. With shares now at $34.89, the stock is trading +0.7% above its intraday low and +0.7% below the session's peak.

Trading volume for Franklin Genomic Advancements(HELX) stock has reached 699, versus its average volume of 200.6.

The stock's 52-week range extends from a low of $23.74 to a high of $35.47.

The stock's 52-week range extends from a low of $23.74 to a high of $35.47.

Average Annual Return

All investments involve risks, including the loss of principal. Performance data represents past performance and is no guarantee of future results. Investment returns and principal value will fluctuate and are subject to market volatility. An investment, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted.